BLD-0409

DRUG3 trials

Sponsors

Blade Therapeutics

Conditions

Chronic Liver DiseaseDrug Drug InteractionNASH - Nonalcoholic SteatohepatitisRelative Bioavailability

Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

CompletedNCT04146805

Blade TherapeuticsChronic Liver Disease, NASH - Nonalcoholic Steatohepatitis

Start: 2020-01-10End: 2021-04-12Updated: 2021-06-04

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

CompletedNCT04814472

Blade TherapeuticsRelative Bioavailability

Start: 2021-05-16End: 2021-11-03Updated: 2021-11-10

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

CompletedNCT04814498

Blade TherapeuticsDrug Drug Interaction

Start: 2021-05-03End: 2022-01-11Updated: 2022-05-17

Related Papers

Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis

2022-09-043 citations